Press release
Geron to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and
About this update from Geron Corporation
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present in-person at the following investor conferences in New York City:\n\n\nMorgan Stanley 20th Annual Global Healthcare Conference\nFireside chat on Monday, September 12, 2022, at 5:25 p.m. ET\n\n\n\nH.C. Wainwright 24th Annual Global Investment Conference\nCorporate presentation on Tuesday, September 13, 2022, at 12:30 p.m. ET\n\n\n\nBaird 2022 Global Healthcare Conference\nFireside chat on Wednesday, September 14, 2022, at 1:25 p.m. ET\n\n\nA webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of Geron’s website under Events. Following each scheduled conference event, the related webcast will be archived and available for replay for a period of 30 days.\n\nAbout Geron\n\nGeron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in relapsed/refractory myelofibrosis.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220901005110/en/\n\nAron Feingold\nInvestor and Media Relations\[email protected]\[email protected]\n\nSource: Geron Corporation","length":3386,"tagName":"div"}]